7 research outputs found
Women's preferences for masculinity in male faces are highest during reproductive age range and lower around puberty and post-menopause
Masculinity in male faces is thought to be a sign of mate quality and is associated with measures of long-term health. Previous studies have demonstrated that women's masculinity preferences change across the menstrual cycle with women preferring more masculine men during phases of the menstrual cycle where fertility is highest (i.e. the late follicular phase). Given the hormonal correlates of such preferences and that these hormones change across the life span, we tested for differences in female masculinity preferences at different ages. We compared the masculinity preferences of peri-pubescent girls and young adult women (Study 1), circummenopausal women reporting to either be pre- or post-menopause (Study 2), and a large sample of women across a wide range of ages (Study 3). In all three studies, preferences for masculinity in male faces were highest in women who were at a reproductively active age. Preferences for masculinity were lower when females were peri-pubescent, post-menopausal, or at ages corresponding to these groups. These data support the notion that masculinity in male faces is an important trait for reproductively relevant mate choice decisions. These data also highlight a shift in female visual preferences for men that is associated with important stages of the lifespan. Visual preferences appear to track important hormonal changes associated with age; as women pass puberty their preferences shift towards facial traits associated with mate quality and as women undergo menopause their preferences for such facial traits decrease. Overall, these results demonstrate the important role of reproductive status and support the notion that preferences for male faces are tied to reproductively relevant hormones
Women's preferences for masculinity in male faces are highest during reproductive age range and lower around puberty and post-menopause
Masculinity in male faces is thought to be a sign of mate quality and is associated with measures of long-term health. Previous studies have demonstrated that women's masculinity preferences change across the menstrual cycle with women preferring more masculine men during phases of the menstrual cycle where fertility is highest (i.e. the late follicular phase). Given the hormonal correlates of such preferences and that these hormones change across the life span, we tested for differences in female masculinity preferences at different ages. We compared the masculinity preferences of pen-pubescent girls and young adult women (Study 1), circum-menopausal women reporting to either be pre- or post-menopause (Study 2), and a large sample of women across a wide range of ages (Study 3). In all three studies, preferences for masculinity in male faces were highest in women who were at a reproductively active age. Preferences for masculinity were lower when females were pen-pubescent, post-menopausal, or at ages corresponding to these groups. These data support the notion that masculinity in male faces is an important trait for reproductively relevant mate choice decisions. These data also highlight a shift in female visual preferences for men that is associated with important stages of the lifespan. Visual preferences appear to track important hormonal changes associated with age; as women pass puberty their preferences shift towards facial traits associated with mate quality and as women undergo menopause their preferences for such facial traits decrease. Overall, these results demonstrate the important role of reproductive status and support the notion that preferences for male faces are tied to reproductively relevant hormones. (C) 2009 Elsevier Ltd. All rights reserved.</p
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: Results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
BACKGROUND:
A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. We aimed to compare combined insulin degludec-liraglutide (IDegLira) with its components given alone in insulin-naive patients.
METHODS:
In this phase 3, 26-week, open-label, randomised trial, adults with type 2 diabetes, HbA1c of 7-10% (inclusive), a BMI of 40 kg/m(2) or less, and treated with metformin with or without pioglitazone were randomly assigned (2:1:1) to daily injections of IDegLira, insulin degludec, or liraglutide (1\ub78 mg per day). IDegLira and insulin degludec were titrated to achieve a self-measured prebreakfast plasma glucose concentration of 4-5 mmol/L. The primary endpoint was change in HbA1c after 26 weeks of treatment, and the main objective was to assess the non-inferiority of IDegLira to insulin degludec (with an upper 95% CI margin of 0\ub73%), and the superiority of IDegLira to liraglutide (with a lower 95% CI margin of 0%). This study is registered with ClinicalTrials.gov, number NCT01336023.
FINDINGS:
1663 adults (mean age 55 years [SD 10], HbA1c 8\ub73% [0\ub79], and BMI 31\ub72 kg/m(2) [4\ub78]) were randomly assigned, 834 to IDegLira, 414 to insulin degludec, and 415 to liraglutide. After 26 weeks, mean HbA1c had decreased by 1\ub79% (SD 1\ub71) to 6\ub74% (1\ub70) with IDegLira, by 1\ub74% (1\ub70) to 6\ub79% (1\ub71) with insulin degludec, and by 1\ub73% (1\ub71) to 7\ub70% (1\ub72) with liraglutide. IDegLira was non-inferior to insulin degludec (estimated treatment difference -0\ub747%, 95% CI -0\ub758 to -0\ub736, p<0\ub70001) and superior to liraglutide (-0\ub764%, -0\ub775 to -0\ub753, p<0\ub70001). IDegLira was generally well tolerated; fewer participants in the IDegLira group than in the liraglutide group reported gastrointestinal adverse events (nausea 8\ub78 vs 19\ub77%), although the insulin degludec group had the fewest participants with gastrointestinal adverse events (nausea 3\ub76%). We noted no clinically relevant differences between treatments with respect to standard safety assessments, and the safety profile of IDegLira reflected those of its component parts. The number of confirmed hypoglycaemic events per patient year was 1\ub78 for IDegLira, 0\ub72 for liraglutide, and 2\ub76 for insulin degludec. Serious adverse events occurred in 19 (2%) of 825 patients in the IDegLira group, eight (2%) of 412 in the insulin degludec group, and 14 (3%) of 412 in the liraglutide group.
INTERPRETATION:
IDegLira combines the clinical advantages of basal insulin and GLP-1 receptor agonist treatment, resulting in improved glycaemic control compared with its components given alone
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
BACKGROUND:
A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. We aimed to compare combined insulin degludec-liraglutide (IDegLira) with its components given alone in insulin-naive patients.
METHODS:
In this phase 3, 26-week, open-label, randomised trial, adults with type 2 diabetes, HbA1c of 7-10% (inclusive), a BMI of 40 kg/m(2) or less, and treated with metformin with or without pioglitazone were randomly assigned (2:1:1) to daily injections of IDegLira, insulin degludec, or liraglutide (1路8 mg per day). IDegLira and insulin degludec were titrated to achieve a self-measured prebreakfast plasma glucose concentration of 4-5 mmol/L. The primary endpoint was change in HbA1c after 26 weeks of treatment, and the main objective was to assess the non-inferiority of IDegLira to insulin degludec (with an upper 95% CI margin of 0路3%), and the superiority of IDegLira to liraglutide (with a lower 95% CI margin of 0%). This study is registered with ClinicalTrials.gov, number NCT01336023.
FINDINGS:
1663 adults (mean age 55 years [SD 10], HbA1c 8路3% [0路9], and BMI 31路2 kg/m(2) [4路8]) were randomly assigned, 834 to IDegLira, 414 to insulin degludec, and 415 to liraglutide. After 26 weeks, mean HbA1c had decreased by 1路9% (SD 1路1) to 6路4% (1路0) with IDegLira, by 1路4% (1路0) to 6路9% (1路1) with insulin degludec, and by 1路3% (1路1) to 7路0% (1路2) with liraglutide. IDegLira was non-inferior to insulin degludec (estimated treatment difference -0路47%, 95% CI -0路58 to -0路36, p<0路0001) and superior to liraglutide (-0路64%, -0路75 to -0路53, p<0路0001). IDegLira was generally well tolerated; fewer participants in the IDegLira group than in the liraglutide group reported gastrointestinal adverse events (nausea 8路8 vs 19路7%), although the insulin degludec group had the fewest participants with gastrointestinal adverse events (nausea 3路6%). We noted no clinically relevant differences between treatments with respect to standard safety assessments, and the safety profile of IDegLira reflected those of its component parts. The number of confirmed hypoglycaemic events per patient year was 1路8 for IDegLira, 0路2 for liraglutide, and 2路6 for insulin degludec. Serious adverse events occurred in 19 (2%) of 825 patients in the IDegLira group, eight (2%) of 412 in the insulin degludec group, and 14 (3%) of 412 in the liraglutide group.
INTERPRETATION:
IDegLira combines the clinical advantages of basal insulin and GLP-1 receptor agonist treatment, resulting in improved glycaemic control compared with its components given alone